Uno studio in aperto, a braccio singolo di profilassi per la stomatite correlata a Datopotamab Deruxtecan (Dato-DXd) in pazienti idonei con carcinoma mammario metastatico o localmente recidivante inoperabile o carcinoma polmonare non a piccole cellule localmente avanzato o metastatico con mutazione del recettore del fattore di crescita epidermico. (TROPION-SWISH)
Uno studio di fase IV, in aperto, a braccio singolo sulla profilassi della stomatite correlata a datopotamab deruxtecan in pazienti eleggibili con carcinoma mammario metastatico o localmente recidivante inoperabile o carcinoma polmonare non a piccole cellule localmente avanzato o metastatico con mutazione del recettore del fattore di crescita epidermico (TROPION-SWISH)
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The purpose of this Phase IV study is to describe the incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in participants receiving prophylactic dexamethasone mouthwash within the first 12 weeks of study treatment (ie, Dato-DXd dosing).
The study will enroll an estimated 100 participants across approximately 35 sites in the U.S. Enrollment of participants is planned to occur over approximately 18 months, with a minimum of 12 weeks of follow-up for each participant after the first Dato-DXd dose.
This study has one arm, and the study population will consist of 2 independent cohorts (approximately 50 participants in each cohort):
- Breast cohort (Cohort 1)
- Lung cohort (Cohort 2)
Participants will receive the study intervention, dexamethasone mouthwash, throughout the duration of their standard of care treatment with Dato-DXd.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 4
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Luoghi di studio
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Ritirato
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Stati Uniti, 71913
- Reclutamento
- Research Site
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- Research Site
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Non ancora reclutamento
- Research Site
-
Glendale, California, Stati Uniti, 91204
- Reclutamento
- Research Site
-
Lakewood, California, Stati Uniti, 90805
- Reclutamento
- Research Site
-
Long Beach, California, Stati Uniti, 90806
- Reclutamento
- Research Site
-
Torrance, California, Stati Uniti, 90505
- Non ancora reclutamento
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20037
- Ritirato
- Research Site
-
-
Florida
-
Coral Springs, Florida, Stati Uniti, 33065
- Reclutamento
- Research Site
-
Plantation, Florida, Stati Uniti, 33322
- Reclutamento
- Research Site
-
-
Georgia
-
Athens, Georgia, Stati Uniti, 30607
- Reclutamento
- Research Site
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Ritirato
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Stati Uniti, 60068
- Ritirato
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Stati Uniti, 46825
- Reclutamento
- Research Site
-
-
Kentucky
-
Elizabethtown, Kentucky, Stati Uniti, 42701
- Reclutamento
- Research Site
-
Lexington, Kentucky, Stati Uniti, 40503
- Reclutamento
- Research Site
-
Lexington, Kentucky, Stati Uniti, 40509
- Non ancora reclutamento
- Research Site
-
Louisville, Kentucky, Stati Uniti, 40207
- Reclutamento
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- Non ancora reclutamento
- Research Site
-
-
Maryland
-
Frederick, Maryland, Stati Uniti, 21702
- Ritirato
- Research Site
-
Glenn Dale, Maryland, Stati Uniti, 20769
- Non ancora reclutamento
- Research Site
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Non ancora reclutamento
- Research Site
-
Grayling, Michigan, Stati Uniti, 49738
- Reclutamento
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55426
- Reclutamento
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Reclutamento
- Research Site
-
-
Nevada
-
Reno, Nevada, Stati Uniti, 89502
- Ritirato
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Ritirato
- Research Site
-
-
New York
-
East Syracuse, New York, Stati Uniti, 13057
- Reclutamento
- Research Site
-
Westbury, New York, Stati Uniti, 11590
- Non ancora reclutamento
- Research Site
-
White Plains, New York, Stati Uniti, 10601
- Ritirato
- Research Site
-
-
North Carolina
-
Greensboro, North Carolina, Stati Uniti, 27403
- Non ancora reclutamento
- Research Site
-
Wilson, North Carolina, Stati Uniti, 27893
- Reclutamento
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Non ancora reclutamento
- Research Site
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Stati Uniti, 19096
- Reclutamento
- Research Site
-
-
South Carolina
-
West Columbia, South Carolina, Stati Uniti, 29169
- Non ancora reclutamento
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37920
- Reclutamento
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Research Site
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Ritirato
- Research Site
-
Morgantown, West Virginia, Stati Uniti, 26506
- Reclutamento
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
Disease Characteristics
-
Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label):
• Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease.
OR
• Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication.
OR
• Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Age
-
Patient must be ≥ 18 years, at the time of signing the informed consent.
Type of Patient and Disease Characteristics-
-
Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.
-
Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.
-
ECOG performance status 0 or 1.
-
Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
-
All women of childbearing potential must have a negative serum pregnancy test result at screening.
Informed Consent
-
Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria apply:
-
Has received Dato-DXd prior to enrollment.
Medical Conditions
-
As judged by the investigator, any evidence of cardiac, pulmonary, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the patient to participate in the study.
-
Has any-grade active and uncontrolled stomatitis or mouth ulcers at baseline (participants with prior medical history of stomatitis or mouth ulcers are eligible).
-
Use of steroid-containing mouthwash is contraindicated in, including but not limited to:
- Active oral infections (eg, viral, bacterial, or fungal), where the use of a steroid-containing mouthwash may impair local immune response and delay healing
- Known hypersensitivity or allergy to corticosteroids or any excipients contained in the mouthwash formulation
-
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localized fungal infections of skin or nails are eligible).
-
Has clinically significant corneal disease.
-
Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients of Dato-DXd (including, but not limited to, polysorbate 80).
-
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
-
Is pregnant, or breastfeeding, or planning to become pregnant.
Other Exclusions
-
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
-
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
-
Previous enrollment in the present study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dexamethasone 0.5 mg/5 mL Mouthwash
Participants will use dexamethasone 0.5 mg/5 mL alcohol-free mouthwash (10 mL, 4 times daily, swish for approximately 2 minutes, then spit out without swallowing). Participants will remain without food or drink for at least 30 minutes after use of dexamethasone |
Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone. Commercially available Dato-DXd is prescribed and administered to participants according to standard of care
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatment
Lasso di tempo: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Incidence is defined as the proportion of participants who develop National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 grade ≥ 2 stomatitis accompanied by either a Normalcy of Diet Subscale score ≤ 50 and/or a Numeric Rating Scale (NRS) oral-pain score of 7 on 2 consecutive days or 8, 9, or 10 on any one day. Severity will be based on the highest NCI-CTCAE v5.0 grade of stomatitis experienced by each participant. CTCAE displays Grades 1-5 with descriptions of severity for each adverse event (AE). Grade 1 for mild symptoms and Grade 5 for death related to AE. The Normalcy of Diet Subscale assesses the degree to which a patient can eat a normal diet and drink liquids. The scale is a ranking of 10 food categories, from easy-to-eat to difficult-to-eat. The Numeric Rating Scale is a scale for self-reporting of pain. Scores range from 0-10, with higher scores meaning the worst pain possible (0=no pain to 10=worst possible pain). |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis
Lasso di tempo: From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
This will be determined using the composite stomatitis definition in the primary outcome. Will be repeated within 6 weeks and within 9 weeks of study treatment. |
From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
|
Incidence and severity of treatment-emergent stomatitis overall, by maximum CTCAE grade, and CTCAE grade ≥ 2
Lasso di tempo: From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
This will be determined using stomatitis CTCAE grade only. Will be analysed at 6, 9 and 12 weeks. |
From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
|
Time to onset of grade ≥ 2 stomatitis
Lasso di tempo: From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
The time (in days) from the date of the first dose of Dato-DXd to the date of first onset to a grade ≥ 2 stomatitis event. The measure of primary interest is median time to onset. |
From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
|
Time to resolution of Dato-DXd-related grade ≥ 2 stomatitis
Lasso di tempo: From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
Number of days from the date of onset of stomatitis grade ≥ 2 until the earliest date of event resolved or reduced in severity to grade 1. The measure of primary interest is median time to resolution. |
From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
|
Proportion of participants with a dose modification for Dato-DXd due to stomatitis
Lasso di tempo: From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
Dose modification is defined as dose reduction, delay, or discontinuation due to stomatitis Treatment-Emergent Adverse Event (TEAE). |
From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
|
Participant adherence to dexamethasone mouthwash
Lasso di tempo: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Adherence to dexamethasone mouthwash will be assessed by cohort using the Daily Activities Diary. The measure of primary interest is the median number of swished mouthwashes per day. |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
|
Safety and tolerability of Dato-DXd in participants receiving prophylactic dexamethasone mouthwash
Lasso di tempo: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Safety and tolerability will be evaluated by cohort in terms of AEs (graded by NCI-CTCAE v5.0) and in terms of the following:
|
From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D926UL00001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Criteri di accesso alla condivisione IPD
When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .